Abstract:Background Growing evidence indicates that lipid metabolism disorders and gut microbiota dysbiosis were related to the progression of non-alcoholic fatty liver disease (NAFLD). Apoptosis-stimulating p53 protein 2 (ASPP2) has been reported to protect against hepatocyte injury by regulating the lipid metabolism, but the mechanisms remain largely unknown. In this study, we investigate the effect of ASPP2 deficiency on NAFLD, lipid metabolism and gut microbiota using ASPP2 globally heterozygous knockout (ASPP2 +/- ) mice. Methods ASPP2 +/- Balb/c mice were fed with methionine and choline deficient diet for 3, 10 and 40 day to induce an early and later-stage of NAFLD, respectively. Fresh fecal samples were collected and followed by 16S rRNA sequencing. HPLC-MRM relative quantification analysis was used to identify changes in hepatic lipid profiles. The expression level of innate immunity-, lipid metabolism- and intestinal permeability-related genes were determined. A spearman’s rank correlation analysis was performed to identify possible correlation between hepatic medium and long-chain fatty acid and gut microbiota in ASPP2-deficiency mice. Results Compared with the WT control, ASPP2-deficiency mice developed moderate steatosis at day 10 and severe steatosis at day 40. The levels of hepatic long chain omega-3 fatty acid, eicosapentaenoic (EPA, 20:5 n-3) and docosahexaenoic (DHA, 22:6 n-3), were decreased at day 10 and increased at day 40 in ASPP +/- mice. Fecal microbiota analysis showed significantly increased alpha and beta diversity, as well as the composition of gut microbiota at the phylum, class, order, family, genus, species levels in ASPP2 +/- mice. Moreover, ASPP-deficiency mice exhibited impaired intestinal barrier function, reduced expression of genes associated with chemical barrier (REG3B, REG3G, Lysozyme and IAP), and increased expression of innate immune components (TLR4 and TLR2). Furthermore, correlation analysis between gut microbiota and fatty acids revealed that EPA was significantly negatively correlated with Bifidobacterium family. Conclusion Our findings suggested that ASPP2-deficiency promotes the progression of NAFLD, alterations in fatty acid metabolism and gut microbiota dysbiosis. The long chain fatty acid EPA was significantly negatively correlated with Bifidobacterial abundance, which is a specific feature of NAFLD in ASPP2-deficiency mice. Totally, the results provide evidence for a mechanism of ASPP2 on dysregulation of fatty acid metabolism and gut microbiota dysbiosis.

The lack of PPARα exacerbated the progression of non-alcoholic steatohepatitis in mice with spleen deficiency syndrome by triggering an inflammatory response

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

Regulation of the Macrophage-Hepatic Stellate Cell Interaction by Targeting Macrophage Peroxisome Proliferator-Activated Receptor Gamma to Prevent Non-Alcoholic Steatohepatitis Progression in Mice

SPP1 and CXCL9 Promote Non-alcoholic Steatohepatitis Progression Based on Bioinformatics Analysis and Experimental Studies

Intestinal peroxisome proliferator-activated receptor -fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis

Regulation of the macrophage‐hepatic stellate cell interaction by targeting macrophage PPARγ to prevent NASH progression in mice

Schisandra Lignans Ameliorate Nonalcoholic Steatohepatitis by Regulating Aberrant Metabolism of Phosphatidylethanolamines

Salidroside may target PPARα to exert preventive and therapeutic activities on NASH

PPARα/γ Agonists and Antagonists Differently Affect Hepatic Lipid Metabolism, Oxidative Stress and Inflammatory Cytokine Production in Steatohepatitic Rats

Hepatocyte-specific deletion of Nlrp6 in mice exacerbates the development of non-alcoholic steatohepatitis

PPARalpha-ERRalpha crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression

Disruption of Adenosine 2A Receptor Exacerbates NAFLD Through Increasing Inflammatory Responses and SREBP1c Activity

Integrating Multi-Omics Reveals Crucial Biomarkers in Non-Alcoholic Fatty Liver Disease

Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice

Dysregulated hepatic lipid metabolism and gut microbiota associated with early-stage NAFLD in ASPP2-deficiency mice

Lack of Nogo-B expression ameliorates PPARγ deficiency-aggravated liver fibrosis by regulating TLR4-NF-κB-TNF-α axis and macrophage polarization

Deletion of the PPAR gene exacerbates high-fat diet-induced nonalcoholic fatty liver disease in mice through the gut-liver axis

Deletion of the PPARδ gene exacerbates high-fat diet-induced nonalcoholic fatty liver disease in mice through the gut-liver axis

Neutrophils Play a Crucial Role in the Early Stage of Nonalcoholic Steatohepatitis Via Neutrophil Elastase in Mice

[Effects of Soothing Liver and Invigorating Spleen Recipes on NF-kappaB Signal Pathway Related Genes and Proteins in Primary Hepatocytes of Rats with NASH].

Host ALDH2 deficiency aggravates nonalcoholic steatohepatitis through gut-liver axis